These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 12153376)
1. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Meyer G; Marjanovic Z; Valcke J; Lorcerie B; Gruel Y; Solal-Celigny P; Le Maignan C; Extra JM; Cottu P; Farge D Arch Intern Med; 2002 Aug 12-26; 162(15):1729-35. PubMed ID: 12153376 [TBL] [Abstract][Full Text] [Related]
2. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Caine GJ; Lip GY Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973 [No Abstract] [Full Text] [Related]
3. International normalized ratio and anticoagulation. Theerman MR Arch Intern Med; 2003 May; 163(10):1242-3; author reply 1244. PubMed ID: 12767971 [No Abstract] [Full Text] [Related]
4. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS; JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909 [TBL] [Abstract][Full Text] [Related]
6. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA; JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719 [TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
8. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR; J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799 [TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M; N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. Signorelli JR; Gandhi AS J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146 [TBL] [Abstract][Full Text] [Related]
12. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR; Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789 [TBL] [Abstract][Full Text] [Related]
13. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Huisman MV; Bounameaux H Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915 [TBL] [Abstract][Full Text] [Related]
14. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448 [TBL] [Abstract][Full Text] [Related]
15. Selecting an anticoagulant for recurrent venous thromboembolism in cancer. Goodin S Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363 [TBL] [Abstract][Full Text] [Related]
16. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Luk C; Wells PS; Anderson D; Kovacs MJ Am J Med; 2001 Sep; 111(4):270-3. PubMed ID: 11566456 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF; Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820 [TBL] [Abstract][Full Text] [Related]
18. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480 [TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095 [TBL] [Abstract][Full Text] [Related]